{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009738","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.249142+00:00","generated_at":"2026-05-16T10:50:41.441691+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Karyopharm reports prelim FY2025 total revenue ~$145M; cash ~$64M; Phase 3 myelofibrosis data due March 2026","bullets":["Preliminary total revenue for 2025 ~$145M; Q4 2025 ~$33M. U.S. XPOVIO net product revenue 2025 ~$115M; Q4 ~$32M.","Cash and investments as of Dec 31, 2025 ~$64M; liquidity expected to fund operations into Q2 2026.","Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026; XPORT-EC-042 endometrial cancer data due mid-2026.","Completed strategic financing transactions to extend cash runway beyond SENTRY readout.","Global patient access expanded: selinexor approved in >50 countries; reimbursement in Spain and China."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009738","json":"https://secwatch.observer/filing/0001193125-26-009738.json","markdown":"https://secwatch.observer/filing/0001193125-26-009738.md","text":"https://secwatch.observer/filing/0001193125-26-009738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/0001193125-26-009738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:41.441691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}